Dicerna Pharmaceuticals, Inc. Company Review & Valuation
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases.
Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope.
Dicerna Pharmaceuticals, Inc.
was founded in 2006 and is headquartered in Cambridge, Massachusetts.